✉news BusinessRetail first seen 9 h ago, last 1 h ago, peak #5

Retail Traders Eye SLS and IBRX After Moderna Joins Nasdaq-100

Original: SLS, IBRX Stocks Draw Retail Chatter As MRNA Lands A Nasdaq-100 Spot – ‘It Will Be SLS Next’

Retail traders are speculating that Sellas Life Sciences (SLS) and ImmunityBio (IBRX) could be the next biotech stocks to gain a Nasdaq-100 inclusion after Moderna (MRNA) landed a spot in the index. Some investors are voicing confidence that SLS will follow, fueling chatter and speculative buying around the smaller biotech names.

Why now: Index inclusion typically drives fund inflows and share price gains, so traders are betting on which stock could be added next.

SLS (Sellas Life Sciences)ImmunityBio (IBRX)Moderna (MRNA)Nasdaq-100

Open on news →

Rank over time, top of the chart is #1. 4 snapshots from 5 h ago to 1 h ago.

Evidence

• SLS, IBRX Stocks Draw Retail Chatter As MRNA Lands A Nasdaq-100 Spot – ‘It Will Be SLS Next’ · Stocktwits

API: https://socialmediatrends-api.osmike.com/v1/trends/928514